Globalspace Technologies Q2 FY27 Results Due November 5

Globalspace Technologies Ltd is scheduled to consider and approve its unaudited Q2 FY27 and half-year results on November 5, 2026, after reporting consolidated sales of ₹14.64 crore for the June 2026 quarter, up 66.7% from ₹8.78 crore a year earlier. The board meeting will also consider the limited review report.

When will Globalspace Technologies announce Q2 FY27 results?

Globalspace Technologies is scheduled to announce unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, at a board meeting on November 5, 2026. The company disclosed the meeting agenda on November 2, stating that directors would consider and approve the results along with the limited review report.

The scheduled announcement falls on the date identified as the company’s expected earnings date. No September-quarter revenue, profit, margin or balance-sheet numbers were provided in the available disclosures before the meeting. Investors will therefore need to rely on the formal results and accompanying exchange filing for the reported Q2 performance.

The company last approved its unaudited June-quarter results on August 14, 2026. Its annual report for FY2025-26 was filed with BSE on September 5, 2026, and the members subsequently adopted audited financial statements for the year ended March 31, 2026, together with the Board of Directors’ report.

What did Globalspace Technologies report in the June 2026 quarter?

Globalspace Technologies reported consolidated sales of ₹14.64 crore for the June 2026 quarter, compared with ₹8.78 crore in the June 2025 quarter, representing year-on-year growth of 66.7%. Consolidated net profit was reported at ₹0.70 crore, up 337.5% from the year-earlier quarter.

The available quarterly product-segment data shows operating profit of ₹3.59 crore in June 2026, compared with ₹0.77 crore in March 2026. Operating profit margin was 24.52% in June 2026, against 4.80% in the preceding quarter. Sales, however, declined from ₹16.04 crore in March 2026 to ₹14.64 crore in June 2026.

Standalone quarterly data presents a separate view. It records revenue of ₹11.18 crore, EBITDA of ₹3.34 crore and net profit of ₹0.99 crore for June 2026. These figures should not be compared directly with consolidated numbers because consolidated accounts include the financial performance of subsidiaries.

How did Globalspace Technologies perform in FY2025-26?

Globalspace Technologies reported standalone revenue of ₹33.35 crore for FY2025-26, compared with ₹29.33 crore in FY2024-25. Standalone EBITDA rose to ₹4.37 crore from ₹0.91 crore, while the company reported a standalone net profit of ₹1.36 crore after a net loss of ₹1.84 crore in the previous year.

The annual figures indicate a return to profitability at the standalone level. Earnings per share were ₹1.19 for FY2025-26, compared with a loss per share of ₹1.66 in FY2024-25. The company did not declare a dividend for the year.

The FY2025-26 annual-report information also showed net debt declining to ₹3.14 crore from ₹9.40 crore. Total equity increased to ₹57.08 crore, while the gearing ratio improved to 5.50% from 17.33%. The company reported unqualified audit opinions and said financial risks are overseen directly by the Board.

What will investors assess in the September-quarter results?

Investors will assess whether Globalspace Technologies maintained the revenue momentum and operating-margin improvement recorded in the June quarter. The June-quarter sales figure was lower sequentially than March, while operating profit and margin improved substantially, making the relationship between revenue growth and profitability a relevant area in the upcoming disclosure.

The September-quarter filing will provide the first reported half-year performance for FY2026-27. It will also allow comparison with the September 2025 quarter, when consolidated sales were ₹10.01 crore and the standalone quarterly data recorded revenue of ₹5.18 crore. Such comparisons must remain within the same reporting basis.

Management’s healthcare technology strategy is another disclosed point of interest. The company stated in its FY2025-26 reporting that it was progressing its AI healthcare platform strategy and was targeting an integrated-solution launch by FY2026-27. The available information does not provide a financial contribution from this initiative, so any update in the results or management commentary will be relevant for understanding its operational status.

Why do the November 5 results matter for Globalspace Technologies shareholders?

The November 5 results matter because they will update shareholders on sales, profitability and cash-position trends following a year in which standalone revenue and EBITDA improved and net debt fell. The formal filing will also provide current data after the June-quarter results, which showed strong year-on-year consolidated sales growth but a sequential decline in sales from March.

For the broader business, the disclosure will clarify the relative contribution of the parent company and subsidiaries to reported performance. Globalspace Technologies has identified Miljon Medi App Private Limited, in which it holds 95%, and Innopharma Healthcare Private Limited, in which it holds 51%, as subsidiaries relevant to its consolidated reporting.

The board meeting is a routine corporate-results event rather than an announced strategic transaction. Still, the Q2 and half-year numbers, limited review report and any management disclosures will be the primary verified sources for evaluating the company’s financial position after September 30, 2026.

Conclusion

Globalspace Technologies enters its November 5 board meeting after reporting ₹14.64 crore of consolidated June-quarter sales, 66.7% higher year on year, alongside an improvement in operating margin to 24.52%. Its FY2025-26 standalone results also showed a move from loss to profit, while debt and gearing declined.

The next item to watch is the board-approved September-quarter and half-year FY2026-27 filing, including reported standalone and consolidated sales, profit, margins and the limited review report. Investors may also look for a disclosed update on the company’s FY2026-27 target to launch an integrated AI healthcare solution.